Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 4

A Multicenter Randomized Trial of EBUS-TBNA Versus Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

NCT ID: NCT06105801Sponsor: Vanderbilt-Ingram Cancer CenterLast updated: 2026-02-02

Summary

This is a multi-center clinical trial evaluating the effect of transbronchial mediastinal cryobiopsy for its ability to improve the likelihood of obtaining tissue sufficient for molecular analysis. Patients in outpatient clinics or pre-operative holding areas planning to undergo a bronchoscopic biopsy of a suspected malignant lesion (peripheral or mediastinal) for initial diagnosis, staging, or tissue acquisition for molecular analysis will be considered for enrollment and consented. Patients will only be enrolled if intraoperative ROSE suggests malignancy. Patients will be randomized to continue with the operator's initial EBUS-TBNA needle or switch to a cryoprobe to perform a sampling.

Detailed description

Primary Objective: \- To evaluate the utility of transbronchial mediastinal cryobiopsy on its ability to improve the likelihood of acquiring tissue sufficient for next-generation sequencing (NGS). Safety Endpoints: * Pneumothorax within 7 days of procedure * Moderate bleeding defined as controlled with bronchoscope, saline, or epinephrine * Serious bleeding is defined as uncontrolled, leading to respiratory failure, need for transfusion, or cardiovascular instability * Respiratory failure is defined as a new oxygen requirement or escalation in oxygen delivery within 7 days of procedure * Unplanned hospitalization related to the procedure within 7 days of procedure * Death Exploratory Endpoints: * The proportion of samples adequate for NGS testing * The proportion of samples with adequate PD-1 / PD-L1 immunohistochemical staining * Proportion of samples that are adequate for complete NGS library sequencing * Estimated total number of tumor cells per H\&E-stained slide * Histological disease subtyping

Arms & interventions

  • ProcedureEndobronchial ultrasound with transbronchial needle aspiration

    Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration

  • ProcedureBronchoscopy

    Participants will undergo Bronchoscopy

  • ProcedureCryobiopsy

    Participants will undergo Cryobiopsy

Outcome measures

Primary

  • Proportion of samples sufficient for next-generation sequencing testing

    Comparison of samples between arms that meet sufficiency criteria for NGS

    Time frame: Up to 12 months

Secondary

  • Proportion of samples with adequate PD-1 / PD-L1 immunohistochemical staining

    Time frame: Up to 12 months

  • Proportion of samples that are adequate for complete NGS library sequencing

    Time frame: Up to 12 months

  • Estimated total number of tumor cells per H&E-stained slide

    Time frame: Up to 12 Months

  • Histological disease subtyping

    Time frame: Up to 12 Months

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Lesions on PET or CT concerning for primary or metastatic malignancy that are amenable to biopsy by linear EBUS * Malignant cells present on rapid on-site cytological evaluation (ROSE) Exclusion Criteria: * Patient is known to be less than 18 years old * Patient is known to be pregnant * Patient is known to be a prisoner * Operator deems lesion is not safe to biopsy

Study locations (1)

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232

Recruiting
Vanderbilt-Ingram Service Services for Timely Access · Contact
Fabien Maldonado, MD · Principal Investigator
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing | Cancerify